Loading…
Alaunos Therapeutics, Inc. is projected to decline to $1.82 by 2027, a -5% move from its current price of $1.91. TCRT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.85 | $1.91 | $1.96 | +0.02% |
| Aug 6 | $1.83 | $1.91 | $1.98 | +0.04% |
| Aug 7 | $1.81 | $1.91 | $2.00 | +0.05% |
| Aug 8 | $1.80 | $1.91 | $2.02 | +0.07% |
| Aug 9 | $1.79 | $1.91 | $2.03 | +0.09% |
| Aug 10 | $1.78 | $1.91 | $2.04 | +0.11% |
| Aug 11 | $1.77 | $1.91 | $2.06 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.77 | $1.91 | $2.06 | +0.13% |
| Week 2 | $1.72 | $1.91 | $2.12 | +0.25% |
| Week 3 | $1.68 | $1.91 | $2.18 | +0.38% |
| Week 4 | $1.65 | $1.91 | $2.22 | +0.50% |
| Week 5 | $1.62 | $1.92 | $2.27 | +0.63% |
| Week 6 | $1.60 | $1.92 | $2.31 | +0.75% |
| Week 7 | $1.58 | $1.92 | $2.34 | +0.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alaunos Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It pursues a non-hormonal, non-incretin approach, and also develops hunTR TCR discovery platform to target driver mutations.
Alaunos Therapeutics, Inc. trades under the symbol TCRT. The current price is $1.92. The stock has a market cap of $4.69M and ranks 5206 in size among listed assets.
A major floor 18.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.3% away) — a key level to hold.
The nearest ceiling, 24.4% above — a clean break opens room to run.
A major ceiling 64.8% above — clearing it would confirm fresh momentum.
Key TCRT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TCRT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.90 | Buy | $1.90 | Buy |
| MA 10 | $1.94 | Sell | $1.94 | Sell |
| MA 20 | $2.01 | Sell | $2.00 | Sell |
| MA 50 | $2.21 | Sell | $2.19 | Sell |
| MA 100 | $2.54 | Sell | $2.42 | Sell |
| MA 200 | $2.82 | Sell | $2.73 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.25 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -110.83 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -11.74 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.56 | Sell |
| Awesome (5,34) | -0.19 | Sell |
| Ultimate (7,14,28) | 24.18 | Buy |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 1.87 | Buy |
| ADX (14) | 21.04 | Sell |
| ATR (14) | 0.04 | Info |
The near-term picture shows BEARISH sentiment. The RSI14 reads 40, indicating modest downside pressure today. The stock trades around the moving averages, with SMA50 at $2.28 and SMA200 at $2.87.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.88 | $1.91 | $2.53 | 0% | Neutral | |
| $1.45 | $1.82 | $2.42 | -5% | Neutral | |
| $1.56 | $2.01 | $2.79 | +6% | Neutral | |
| $1.71 | $2.27 | $3.25 | +19% | Neutral | |
| $1.86 | $2.53 | $3.70 | +33% | Bullish | |
| $2.00 | $2.77 | $4.15 | +45% | Bullish | |
| $1.81 | $2.55 | $3.89 | +34% | Bullish | |
| $1.79 | $2.56 | $3.98 | +34% | Bullish | |
| $1.91 | $2.78 | $4.38 | +46% | Bullish | |
| $1.84 | $2.72 | $4.35 | +43% | Bullish | |
| $2.29 | $3.64 | $6.22 | +91% | Bullish | |
| $4.25 | $7.62 | $14.29 | +300% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.88 | $1.91 | $2.30 | +0.00% |
| September 2026 | $1.59 | $1.89 | $2.30 | -0.94% |
| October 2026 | $1.62 | $1.94 | $2.38 | +2.61% |
| November 2026 | $1.69 | $2.03 | $2.52 | +4.77% |
| December 2026 | $1.67 | $2.02 | $2.53 | -0.47% |
Click any year to see its month-by-month TCRT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Alaunos Therapeutics, Inc.'s 2026 outlook centres on $1.91, within a $1.88 to $2.53 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TCRT could reach as high as $2.42, with a base case around $1.82 and support toward $1.45 — roughly -5% from $1.91. A consolidation phase looks the most probable path here.
Expect TCRT to range from $1.56 to $2.79 through 2028. The $2.01 average target implies a +6% move from current prices. That is up +11% on the projected 2027 average. Price action looks broadly range-bound.
The TCRT price prediction for 2029 points to an average of $2.27 (low $1.71, high $3.25) — a potential gain of +19% on today's $1.91. A consolidation phase looks the most probable path here.
In 2030, TCRT is projected to trade between $1.86 and $3.70, averaging $2.53 — a potential gain of +33% from today's $1.91. That is up +11% on the projected 2029 average. Momentum favours further upside here.
Alaunos Therapeutics, Inc.'s 2031 outlook centres on $2.77, within a $2.00 to $4.15 range. That is up +10% on the projected 2030 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TCRT could reach as high as $3.89, with a base case around $2.55 and support toward $1.81 — roughly +34% from $1.91. Momentum favours further upside here.
Expect TCRT to range from $1.79 to $3.98 through 2033. The $2.56 average target implies a +34% move from current prices. That is up +1% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TCRT price prediction for 2034 points to an average of $2.78 (low $1.91, high $4.38) — a potential gain of +46% on today's $1.91. Momentum favours further upside here.
In 2035, TCRT is projected to trade between $1.84 and $4.35, averaging $2.72 — a potential gain of +43% from today's $1.91. That is -2% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Alaunos Therapeutics, Inc.'s 2040 outlook centres on $3.64, within a $2.29 to $6.22 range. That is up +34% on the projected 2035 average. That marks a +91% change versus current levels. Momentum favours further upside here.
By 2050, TCRT could reach as high as $14.29, with a base case around $7.62 and support toward $4.25 — roughly +300% from $1.91. Buyers look set to stay in control over this stretch.
Investing $1,000 in TCRT today (≈ 524.934383 TCRT) could be worth
$4,002.19
+$3,002.19 (+300%) by 2050 · US Dollar
Based on the average projected TCRT price of $7.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TCRTwould be worth at today's price.
$1,000 invested in TCRT on Jul 31, 2025 (≈ 350.877205 TCRT) would be worth
$668.42
-$331.58 (-33.2%) today · 0.67× · US Dollar
Based on a TCRT entry price of $2.85 vs. today's $1.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.94 | $981.96 | -1.8% |
| 1 month ago | $2.16 | $881.94 | -11.8% |
| 3 months ago | $2.61 | $729.89 | -27.0% |
| 6 months ago | $2.75 | $692.73 | -30.7% |
| 1 year ago | $2.85 | $668.42 | -33.2% |
| All time (5.0y) ago | $346.5 | $5.5 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TCRT forecast.
Our base-case forecast reaches $3.80 around 2050.
Implied market cap at $3.80: $9.28M
The multi-year forecast points to a bullish tilt later in the horizon. In 2030, the avg price is $2.59 with a max of $3.95 and a min of $1.84, representing a 35% ROI. By 2040 the avg price is $3.60 with a max of $6.53 and a 87.3% ROI, and by 2050 the avg price is $7.66 with a max of $15.40 and a 298.7% ROI.
The sequence shows a progression from neutral to bullish sentiment across the horizon, with higher price targets and return potential in the outer years; these are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $2.59, min $1.84, max $3.95, ROI 35%, sentiment BULLISH.
Forecasts show a bullish trajectory in later years with 2030 avg $2.59 (ROI 35%), 2040 avg $3.60 (ROI 87.3%), and 2050 avg $7.66 (ROI 298.7%). Near term shows neutral to flat outlook in 2026–2029; these are estimates and not guarantees.
2031 max is $4.43, so reaching $5 by 2031 is not indicated by the forecast.
Current price $1.92; Market cap $4.69M; Rank 5206.
Sentiment is BEARISH. RSI14 is 40. SMA50 is $2.28 and SMA200 is $2.87. Support is at $1.92 and resistance at $2.37. The thirty-day range is $1.54 to $2.40, and annualized volatility is 60%.
Alaunos Therapeutics, Inc. Community Discussion
0Share your Alaunos Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.